Biomedical subjects

Donald Hedeker

Publications and source records attributed to Donald Hedeker.

3 recordsLinked to original sources

PubMed2003

A mixed-effects multinomial logistic regression model.

A mixed-effects multinomial logistic regression model is described for analysis of clustered or longitudinal nominal or ordinal response data. The model is parameterized to allow flexibility in the choice of contrasts used to represent comparisons across the response categories. Estimation is achieved using a maximum marginal likelihood (MML) solution that uses quadrature to numerically integrate over the distribution of random effects. An analysis of a psychiatric data set, in which homeless adults with serious mental illness are repeatedly classified in terms of their living arrangement, is used to illustrate features of the model.

Adult↗

PubMed2003

Extended telephone counseling for smoking cessation: does content matter?

Telephone counseling is a popular modality for smoking cessation treatment; however, little attention has been paid to evaluating the efficacy of different contents of calls. This study compared 2 types of proactive telephone calls following a group program. Participants were randomized to receive either: (a) basic content, consisting primarily of support; or (b) enhanced content, tailored to the stage of cessation (still smoking, abstinent, or relapsed) and targeting factors hypothesized to be related to success (motivation, self-efficacy, and negative mood). There was a significant interaction between treatment condition and gender. For men, the enhanced condition produced better abstinence rates through 15 months and lower relapse rates. For women, the basic condition was better. History of depression did not interact with condition.

Adult↗

PubMed2002

Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment.

The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.

Adult↗